^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    VEGF-C inhibitor

    Related drugs:
    2ms
    4D-150 in Patients With Diabetic Macular Edema (clinicaltrials.gov)
    P2, N=72, Active, not recruiting, 4D Molecular Therapeutics | Recruiting --> Active, not recruiting | Trial completion date: Jul 2028 --> Feb 2029 | Trial primary completion date: Feb 2028 --> Feb 2029
    Enrollment closed • Trial completion date • Trial primary completion date
    5ms
    4FRONT-2: Single Intravitreal Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration (clinicaltrials.gov)
    P3, N=400, Recruiting, 4D Molecular Therapeutics
    New P3 trial
    5ms
    PRISM: 4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration (clinicaltrials.gov)
    P1/2, N=215, Recruiting, 4D Molecular Therapeutics | Trial completion date: Nov 2026 --> Jan 2031 | Trial primary completion date: Nov 2025 --> Mar 2027
    Trial completion date • Trial primary completion date
    8ms
    A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema (clinicaltrials.gov)
    P1/2, N=153, Completed, Opthea Limited | Phase classification: P1b/2a --> P1/2
    Phase classification
    8ms
    ShORe: OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) (clinicaltrials.gov)
    P3, N=986, Terminated, Opthea Limited | Trial completion date: Jul 2026 --> Mar 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2025 --> Mar 2025; The primary endpoint was not achieved in the study.
    Trial completion date • Trial termination • Trial primary completion date
    |
    Lucentis (ranibizumab)
    8ms
    COAST: OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD) (clinicaltrials.gov)
    P3, N=998, Terminated, Opthea Limited | Trial completion date: Jul 2026 --> Mar 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2025 --> Mar 2025; The primary endpoint was not achieved in the study.
    Trial completion date • Trial termination • Trial primary completion date
    9ms
    4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration (clinicaltrials.gov)
    P3, N=400, Recruiting, 4D Molecular Therapeutics
    New P3 trial
    1year
    PRISM: 4D-150 in Patients with Neovascular (Wet) Age-Related Macular Degeneration (clinicaltrials.gov)
    P1/2, N=215, Recruiting, 4D Molecular Therapeutics | N=150 --> 215 | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2024 --> Nov 2025
    Enrollment change • Trial completion date • Trial primary completion date • Gene therapy
    over1year
    A Dose Escalation Study of IBI333 in Subjects With Neovascular Age-related Macular Degeneration (clinicaltrials.gov)
    P1, N=17, Completed, Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruiting --> Completed
    Trial completion
    over1year
    ShORe: OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) (clinicaltrials.gov)
    P3, N=990, Active, not recruiting, Opthea Limited | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy
    |
    Lucentis (ranibizumab)
    over1year
    DISCOVER: Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD) (clinicaltrials.gov)
    P1/2, N=15, Active, not recruiting, AsclepiX Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    over1year
    Study of IBI333 in Subjects With Neovascular Age-related Macular Degeneration (clinicaltrials.gov)
    P1, N=17, Active, not recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Jan 2024 --> Apr 2024
    Enrollment closed • Trial completion date